688197 首药控股
已收盘 12-26 15:00:01
资讯
新帖
简况
首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿
中金财经 · 12-26 17:19
首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿
首药控股筹划发行H股并在香港联交所上市
中金财经 · 12-14
首药控股筹划发行H股并在香港联交所上市
首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市
智通财经网 · 12-12
首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市
破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿
中金财经 · 12-11
破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿
12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股
证券之星 · 12-02
12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股
11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股
证券之星 · 11-07
11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股
每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%
证券之星 · 11-02
每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%
首药控股公布国际专利申请：“一种抑制剂杂环化合物”
证券之星 · 11-02
首药控股公布国际专利申请：“一种抑制剂杂环化合物”
图解首药控股三季报：第三季度单季净利润同比增长11.78%
证券之星 · 10-30
图解首药控股三季报：第三季度单季净利润同比增长11.78%
首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%
中金财经 · 10-30
首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%
首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%
证券之星 · 10-30
首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%
每周股票复盘：首药控股（688197）索特替尼片上市申请获受理
证券之星 · 10-26
每周股票复盘：首药控股（688197）索特替尼片上市申请获受理
首药控股(688197.SH)：RET抑制剂索特替尼片(SY-5007)新药上市申请获得受理
智通财经 · 10-22
首药控股(688197.SH)：RET抑制剂索特替尼片(SY-5007)新药上市申请获得受理
首药控股上半年亏1.04亿 2022上市募15亿中信建投保荐
中金财经 · 10-09
首药控股上半年亏1.04亿 2022上市募15亿中信建投保荐
【机构调研记录】长安基金调研首药控股
证券之星 · 09-22
【机构调研记录】长安基金调研首药控股
每周股票复盘：首药控股（688197）SY-5007将报产，SY-3505完成入组
证券之星 · 09-21
每周股票复盘：首药控股（688197）SY-5007将报产，SY-3505完成入组
首药控股：9月4日接受机构调研，中信建投证券、交银施罗德等多家机构参与
证券之星 · 09-19
首药控股：9月4日接受机构调研，中信建投证券、交银施罗德等多家机构参与
每周股票复盘：首药控股（688197）股东户数增5.33%，中报营收降47.37%
证券之星 · 08-31
每周股票复盘：首药控股（688197）股东户数增5.33%，中报营收降47.37%
首药控股(688197)6月30日股东户数0.45万户，较上期增加5.33%
证券之星 · 08-28
首药控股(688197)6月30日股东户数0.45万户，较上期增加5.33%
图解首药控股中报：第二季度单季净利润同比下降8.23%
证券之星 · 08-27
图解首药控股中报：第二季度单季净利润同比下降8.23%
加载更多
公司概况
公司名称：
首药控股(北京)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-23
主营业务：
首药控股(北京)股份有限公司的主营业务是从事小分子靶向创新药的研发。公司的主要产品是肿瘤和糖尿病药物。
发行价格：
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股","latestPrice":35.3,"timestamp":1766732401000,"preClose":36.82,"halted":0,"volume":1489902,"delay":0,"changeRate":-0.0413,"floatShares":64004900,"shares":149000000,"eps":-1.3901,"marketStatus":"已收盘","change":-1.52,"latestTime":"12-26 15:00:01","open":36.77,"high":36.84,"low":35.2,"amount":53158700,"amplitude":0.0445,"askPrice":35.38,"askSize":8,"bidPrice":35.3,"bidSize":81,"shortable":0,"etf":0,"ttmEps":-1.3901,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":36.82,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":40.5,"lowLimit":33.14,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":8.02,"roa":"--","roe":"--","epsLYR":-1.43,"committee":0.186747,"marketValue":5250000000,"turnoverRate":0.0233,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","afterMarket":{"amount":0,"volume":0,"close":35.3,"buyVolume":5500,"sellVolume":0,"time":1766734437768,"indexStatus":"已收盘 12-26 15:30:00","preClose":36.82},"floatMarketCap":2259000000},"requestUrl":"/m/hq/s/688197","defaultTab":"news","newsList":[{"id":"2594260544","title":"首药控股跌4.13% 前三季亏1.55亿2022年上市募15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2594260544","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594260544?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:19","pubTimestamp":1766740755,"startTime":"0","endTime":"0","summary":"中国经济网北京12月26日讯 首药控股 今日股价收报35.30元，跌幅4.13%。目前该股处于破发状态。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。 首药控股近年连续亏损，2021年至2024年，公司归属于上市公司股东的净利润分别为-1.449亿元、-1.738亿元、-1.856亿元、-2.119亿元，归属于上市公司股东的扣除非经常性损益的净利润分别为-1.626亿元、-1.990亿元、-1.994亿元、-2.350亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251226/31895117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2591659935","title":"首药控股筹划发行H股并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591659935","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591659935?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:12","pubTimestamp":1765671156,"startTime":"0","endTime":"0","summary":"中访网数据 首药控股(北京)股份有限公司于今日发布公告，宣布正在筹划发行境外股份(H股)并在香港联合交易所有限公司主板上市的相关事项。 根据公告，公司目前正与相关中介机构就本次H股上市的具体推进工作进行商讨，包括发行规模、定价机制、时间安排等在内的诸多细节尚未最终确定。公司明确表示，本次H股上市计划不会导致公司控股股东和实际控制人发生变更。 本次发行上市计划需履行一系列严格的审议和监管程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2590282572","title":"首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590282572","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590282572?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:46","pubTimestamp":1765532765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司为进一步提升核心竞争力与品牌影响力，充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H股)并在香港联合交易所有限公司(以下简称“香港联交所”)上市事宜。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"首药控股(688197.SH)筹划境外发行股份(H股)并在香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2590593499","title":"破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2590593499","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590593499?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:07","pubTimestamp":1765440424,"startTime":"0","endTime":"0","summary":"中国经济网北京12月11日讯 首药控股 近日发布2025年第三季度报告显示，2025年第三季度，公司归属于上市公司股东的净利润-5039.54万元；归属于上市公司股东的扣除非经常性损益的净利润-5458.78万元。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/11/20251211461485.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/11/20251211461485.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251211/31859231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2588080561","title":"12月2日首药控股跌5.25%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080561","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588080561?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:32","pubTimestamp":1764660746,"startTime":"0","endTime":"0","summary":"证券之星消息，12月2日首药控股跌5.25%，收盘报39.18元，换手率2.37%，成交量1.52万手，成交额6013.65万元。该股为医药、创新药概念热股。重仓首药控股的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7501，较上一交易日下跌0.56%，近一年上涨57.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","688197","BK1574","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2581072660","title":"11月7日首药控股跌5.46%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581072660?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:17","pubTimestamp":1762503441,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日首药控股跌5.46%，收盘报38.98元，换手率2.41%，成交量1.54万手，成交额6107.9万元。该股为医药、创新药概念热股。重仓首药控股的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7839，较上一交易日下跌0.2%，近一年上涨62.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700024837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197","BK1161","BK1574","09939","BK1515","159938"],"gpt_icon":0},{"id":"2580477998","title":"每周股票复盘：首药控股（688197）股东户数增13.7%，前三季营收降47.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580477998","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580477998?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:30","pubTimestamp":1762039839,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，首药控股报收于41.68元，较上周的39.9元上涨4.46%。本周，首药控股10月31日盘中最高价报41.96元。股本股东变化股东户数变动截至2025年9月30日，首药控股股东户数为5146户，较6月30日增加620户，增幅13.7%。业绩披露要点财务报告首药控股2025年三季报显示，前三季度主营收入200.0万元，同比下降47.37%；归母净利润-1.55亿元，同比上升3.26%；扣非净利润-1.69亿元，同比上升1.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0},{"id":"2580647149","title":"首药控股公布国际专利申请：“一种抑制剂杂环化合物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580647149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580647149?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:21","pubTimestamp":1762032073,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示首药控股（688197）公布了一项国际专利申请，专利名为“一种抑制剂杂环化合物”，专利申请号为PCT/CN2025/090983，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来首药控股已公布的国际专利申请5个，与去年同期持平。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了1.08亿元，同比增1%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2579145949","title":"图解首药控股三季报：第三季度单季净利润同比增长11.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579145949","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579145949?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:53","pubTimestamp":1761825205,"startTime":"0","endTime":"0","summary":"证券之星消息，首药控股2025年三季报显示，前三季度公司主营收入200.0万元，同比下降47.37%；归母净利润-1.55亿元，同比上升3.26%；扣非净利润-1.69亿元，同比上升1.87%；其中2025年第三季度，公司单季度主营收入0.0万元，单季度归母净利润-5039.54万元，同比上升11.78%；单季度扣非净利润-5458.78万元，同比上升12.19%；负债率14.12%，投资收益675.63万元，财务费用-49.59万元。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0},{"id":"2579622119","title":"首药控股（688197）披露召开2025年第三季度业绩说明会公告，10月30日股价下跌2.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579622119","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579622119?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:14","pubTimestamp":1761819267,"startTime":"0","endTime":"0","summary":"近日，首药控股(北京)股份有限公司发布公告称，公司将于2025年11月18日上午9:00-10:00通过上海证券交易所上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司前三季度运营情况、创新药物研发进展及未来发展理念。投资者可于11月18日登录上证路演中心在线参与，或于11月11日至17日16:00前通过上证路演中心“提问预征集”栏目或公司邮箱shouyaoholding@163.com提前提交问题。会后可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31751605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2579118608","title":"首药控股(688197)9月30日股东户数0.51万户，较上期增加13.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118608","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118608?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816498,"startTime":"0","endTime":"0","summary":"证券之星消息，近日首药控股披露，截至2025年9月30日公司股东户数为5146.0户，较6月30日增加620.0户，增幅为13.7%。户均持股数量由上期的3.29万股减少至2.89万股，户均持股市值为130.34万元。在化学制药行业个股中，首药控股股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，首药控股区间涨幅为24.59%，在此期间股东户数增加620.0户，增幅为13.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2578850059","title":"每周股票复盘：首药控股（688197）索特替尼片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2578850059","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578850059?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:23","pubTimestamp":1761423787,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，首药控股报收于39.9元，较上周的39.93元下跌0.08%。本周，首药控股10月22日盘中最高价报40.95元。本周关注点公司公告汇总：索特替尼片新药上市申请获国家药监局受理。公司公告汇总首药控股（北京）股份有限公司自愿披露，其自主研发的索特替尼片新药上市申请已获国家药品监督管理局受理，适用于RET基因融合阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2577509343","title":"首药控股(688197.SH)：RET抑制剂索特替尼片(SY-5007)新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2577509343","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577509343?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:13","pubTimestamp":1761127998,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司完全自主研发的索特替尼片(SY-5007，申报商品名：首亦泽®)单药适用于转染重排(RET)基因融合阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者治疗的新药上市申请(NDA)获得受理。SY-5007在RET融合阳性非小细胞肺癌初治及经治患者中均展现出显著且持久的疗效，同时具备良好的安全性与耐受性，充分验证了其作为高选择性RET抑制剂的临床潜力，有望为我国RET融合驱动的非小细胞肺癌患者提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SY","BK4563","BK0239","688197","BK4503","BK4077"],"gpt_icon":0},{"id":"2574336186","title":"首药控股上半年亏1.04亿 2022上市募15亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2574336186","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574336186?lang=zh_cn&edition=full","pubTime":"2025-10-09 11:15","pubTimestamp":1759979708,"startTime":"0","endTime":"0","summary":"中国经济网北京10月9日讯 首药控股 披露的2025年半年度报告显示，2025年上半年，公司实现营业收入200万元，同比下降47.37%；归属于上市公司股东的净利润-1.04亿元，上年同期为-1.03亿元；归属于上市公司股东的扣除非经常性损益的净利润-1.14亿元，上年同期为-1.10亿元；经营活动产生的现金流量净额为-1.14亿元，上年同期为-9714.08万元。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/09/20251009806798.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/09/20251009806798.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251009/31691893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","BK0239","688197","601066"],"gpt_icon":0},{"id":"2569627656","title":"【机构调研记录】长安基金调研首药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569627656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569627656?lang=zh_cn&edition=full","pubTime":"2025-09-22 08:01","pubTimestamp":1758499319,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月19日披露的机构调研信息，长安基金近期对1家上市公司进行了调研，相关名单如下：1）首药控股 调研纪要：SY-707在PFS和安全性方面优于对照药，CDE已完成核查并收到补充资料通知，预计明年获批上市。长安基金成立于2011年，截至目前，资产管理规模144.49亿元，排名133/210；资产管理规模91.5亿元，排名123/210；管理公募基金数50只，排名103/210；旗下公募基金经理9人，排名112/210。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2569246930","title":"每周股票复盘：首药控股（688197）SY-5007将报产，SY-3505完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2569246930","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569246930?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:21","pubTimestamp":1758399668,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，首药控股报收于45.9元，较上周的44.35元上涨3.49%。机构调研要点：SY-3505两个注册性试验已于2025年上半年完成全部受试者入组，目前处于随访阶段。答：公司将全力推进接近商业化的候选药物关键性临床试验及上市申报进度，巩固临床能力，优化开发策略，配合CDE做好SY-707的NDA审评审批，并尽快提交SY-5007的正式NDA；同时高效推进SY-3505注册临床试验随访工作。答：CDE已完成SY-707研制、生产及临床现场核查，注册检验已完成。问：SY-5007的报产计划？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2568251801","title":"首药控股：9月4日接受机构调研，中信建投证券、交银施罗德等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2568251801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568251801?lang=zh_cn&edition=full","pubTime":"2025-09-19 17:36","pubTimestamp":1758274588,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年9月19日首药控股发布公告称公司于2025年9月4日接受机构调研，中信建投证券、交银施罗德、中加基金、华夏基金、泓德基金、长安基金、中航基金、兴合基金、宏利基金、兴业基金、招商信诺、西南证券、禾永投资、投资者、华创证券、开源证券、首创证券、天风证券、工银瑞信基金、华商基金、国金基金参与。首药控股主营业务：肿瘤和糖尿病药物的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900026747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1564","BK0239","BK1147","688197","06066"],"gpt_icon":0},{"id":"2563835514","title":"每周股票复盘：首药控股（688197）股东户数增5.33%，中报营收降47.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563835514","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563835514?lang=zh_cn&edition=full","pubTime":"2025-08-31 09:07","pubTimestamp":1756602430,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，首药控股报收于46.11元，较上周的50.93元下跌9.46%。本周，首药控股8月25日盘中最高价报53.55元。股本股东变化股东户数变动截至2025年6月30日，首药控股股东户数为4526.0户，较3月31日增加229.0户，增幅5.33%。业绩披露要点财务报告首药控股2025年中报显示，公司主营收入200.0万元，同比下降47.37%；归母净利润-1.04亿元，同比下降1.48%；扣非净利润-1.14亿元，同比下降3.97%。截至2025年6月30日，累计使用募集资金1,102,682,065.36元，募集资金账户余额17,222,792.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0},{"id":"2562345082","title":"首药控股(688197)6月30日股东户数0.45万户，较上期增加5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562345082","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562345082?lang=zh_cn&edition=full","pubTime":"2025-08-28 17:27","pubTimestamp":1756373242,"startTime":"0","endTime":"0","summary":"证券之星消息，近日首药控股披露，截至2025年6月30日公司股东户数为4526.0户，较3月31日增加229.0户，增幅为5.33%。在化学制药行业个股中，首药控股股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.3万户。从股价来看，2025年3月31日至2025年6月30日，首药控股区间涨幅为15.99%，在此期间股东户数增加229.0户，增幅为5.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800033140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2562735712","title":"图解首药控股中报：第二季度单季净利润同比下降8.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562735712","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562735712?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:24","pubTimestamp":1756290270,"startTime":"0","endTime":"0","summary":"证券之星消息，首药控股2025年中报显示，公司主营收入200.0万元，同比下降47.37%；归母净利润-1.04亿元，同比下降1.48%；扣非净利润-1.14亿元，同比下降3.97%；其中2025年第二季度，公司单季度主营收入0.0万元，单季度归母净利润-5362.07万元，同比下降8.23%；单季度扣非净利润-5825.43万元，同比下降9.79%；负债率14.01%，投资收益412.55万元，财务费用-40.04万元。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700039340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766781054183,"stockEarnings":[{"period":"1week","weight":-0.047},{"period":"1month","weight":-0.149},{"period":"3month","weight":-0.2363},{"period":"6month","weight":0.0014},{"period":"1year","weight":0.185},{"period":"ytd","weight":0.183}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5146人(较上一季度增加13.70%)","perCapita":"12437股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢19层1单元2202-2号","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是从事小分子靶向创新药的研发。公司的主要产品是肿瘤和糖尿病药物。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股,688197,首药控股股票,首药控股股票老虎,首药控股股票老虎国际,首药控股行情,首药控股股票行情,首药控股股价,首药控股股市,首药控股股票价格,首药控股股票交易,首药控股股票购买,首药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}